Bio-Tissue

11 articles about Bio-Tissue

• TissueTech Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug TTBT01

  3/1/2021

  Bio-Tissue, Inc., a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that its parent company TissueTech had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using morselized Cryopreserved Amniotic Membrane (CAM) and Cryopreserved Umbilical Cord (CUC) Investigational New Drug

• Bio-Tissue, Inc. Highlights Publication of DREAM Study

  6/20/2018

  Bio-Tissue, Inc. highlighted the publication of the DRy Eye Amniotic Membrane (DREAM) study in Clinical Ophthalmology.*

• TissueTech, Inc. Awarded Patent for Compositions of Morselized Umbilical Cord and Amniotic Membrane

  5/14/2018

  TissueTech Inc., the pioneer in the development and clinical application of regenerative amniotic tissue-based products, announced that it has been awarded patent 9,808,491 by the U.S. Patent Trademark Office.

• Bio-Tissue Announces Study that Demonstrates Cryopreserved Amniotic Membrane Graft Reduces Recurrence After Pterygium Surgery

  11/27/2017

  In this retrospective review, 556 eyes representing 535 patients, who had pterygium excision (527 primary, 29 recurrent) were treated with adjunctive cryopreserved amniotic membrane.

• Bio-Tissue Announces First Study to Demonstrate Corneal Nerve Regeneration in Patients With Dry Eye Disease With the Use of PROKERA

  11/10/2017

  The study results will be presented at the upcoming American Academy of Ophthalmology (AAO) meeting taking place November 11 – 14, 2017 in New Orleans.

• Bio-Tissue Announces Strategic Agreement With Bright Optical To Promote Its Regenerative Healing Technology In Canada

  10/4/2017

• Bio-Tissue Announces Strategic Agreement With a Bright Optical To Promote Its Regenerative Healing Technology In Canada

  10/3/2017

• Bio-Tissue Announces Strategic Agreement With Scope To Expand Market Presence In The UK And Ireland

  8/1/2017

• Bio-Tissue™ Trending At 35 Percent Compound Growth, 33 Percent Unit Growth

  1/27/2014

• Bio-Tissue Reaches Major Milestone

  6/1/2011

• Bio-Tissue Appoints Andy Wasserman as VP of Sales & Marketing

  1/27/2009